[8-K] PALVELLA THERAPEUTICS, INC. Reports Material Event

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. furnished an update that it will announce its financial results for the quarter ended September 30, 2025 and hold an earnings call on November 11, 2025. The company attached its press release as Exhibit 99.1 and an earnings call slide presentation as Exhibit 99.2.

The materials are furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes under the Exchange Act, except as expressly incorporated by reference. Palvella’s common stock trades on the Nasdaq Capital Market under the symbol PVLA.

false000158364800015836482025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

Palvella Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			001-37471	30-0784346
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
353 W. Lancaster Ave, Suite 200
Wayne, Pennsylvania				19087
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 11, 2025, Palvella Therapeutics, Inc. (the “Company”) expects to issue a press release announcing its financial results for the quarter ended September 30, 2025. In light of the U.S. national holiday on November 11, 2025, the Company is furnishing a copy of such press release as Exhibit 99.1 to this Current Report on Form 8-K and such press release is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On November 11, 2025, the Company expects to hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Palvella Therapeutics, Inc., dated November 11, 2025*
99.2		Earnings Call Presentation of Palvella Therapeutics, Inc., dated November 11, 2025*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Palvella Therapeutics, Inc.
Date:	November 10, 2025	By:	/s/ Matthew Korenberg
			Matthew Korenberg
			Chief Financial Officer

FAQ

When will PVLA announce its quarterly results?

On November 11, 2025, Palvella will announce results for the quarter ended September 30, 2025.

What exhibits were included with PVLA’s 8-K?

The 8-K furnishes Exhibit 99.1 (press release dated November 11, 2025) and Exhibit 99.2 (earnings call presentation dated November 11, 2025).

Are the earnings materials considered filed or furnished?

They are furnished, not deemed “filed,” under Items 2.02 and 7.01, unless specifically incorporated by reference.

What period do the upcoming results cover for PVLA?

The financial results cover the quarter ended September 30, 2025.

Where is PVLA listed and what is its ticker?

Palvella’s common stock trades on The Nasdaq Capital Market under ticker PVLA.

Will there be an earnings call for PVLA’s Q3 2025 results?

Yes. The company expects to hold an earnings call on November 11, 2025 and furnished a slide deck as Exhibit 99.2.